New drug combo trial offers hope for aggressive blood cancer
NCT ID NCT05376111
Summary
This study is testing whether combining two drugs, venetoclax and azacitidine, is safe and effective as an initial treatment for adults with a fast-growing type of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL). The trial will enroll 28 newly diagnosed patients to see how well they respond to this combination and monitor their survival and any side effects. The goal is to control the disease and achieve remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.